Ernexa Therapeutics Inc. Warrants
ERNAW
NASDAQ Capital Market0.02
USD
+0.00
- -
CIK
0000748592
ISIN
US1140821182
CUSIP
114082118
Return %
Stock
S&P500
1Y
-78.50
14.20
3Y
-78.50
82.01
5Y
-78.50
69.45
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Sanjeev Luther
- Full Time Employees
- 5
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 10355 Science Center Drive Cambridge MA United States of America 02141
- IPO Date
- Jul 12, 2024
- CIK
- 0000748592
- Website
- ernexatx.com
- Similar Companies
- Business
- Ernexa Therapeutics Inc., a preclinical-stage biopharmaceutical company, focuses on the development of allogenic induced pluripotent stem cell–derived mesenchymal stem cell (iMSC) therapies for solid tumors and autoimmune diseases. The company’s lead programs include ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for ovarian cancer, and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for rheumatoid arthritis, with additional candidates advancing in preclinical development. Ernexa operates under licensed collaborations and leverages off-the-shelf cellular platforms to enable scalable, regulated therapeutic products. Founding year and headquarters: Founded in 2018; headquarters location is Cambridge, Massachusetts. The company maintains operations and development activities in the United States, with a focus on advancing preclinical assets toward clinical readiness and potential future clinical trials. Recent major changes and strategic moves (latest 1–2 years): Rebranded from Eterna Therapeutics Inc. to Ernexa Therapeutics in March 2025 to align with strategic focus; establishes ErnexaTX2, a Texas-based subsidiary formed to support ongoing preclinical development of ERNA-101 and to underpin anticipated clinical activities in 2026; reports ongoing execution toward clinical milestones, including advancement of ERNA-101 and ERNA-201 programs and exploration of strategic collaborations to accelerate clinical development and regulatory strategy. These steps reflect a shift toward expanded operational footprint, increased preclinical and regulatory readiness, and disciplined resource allocation to drive first-in-human initiatives. Industry and segments: Biotechnology; cell therapy; regenerative medicine; immuno-oncology; autoimmune diseases. Geographic footprint: United States with research and development activities in Massachusetts and Texas for preclinical and potential clinical operations; potential collaborations and partnerships may extend to international regulators and clinical development networks as programs progress. Subsidiaries and corporate relationships: Wholly owned subsidiary ErnexaTX2 in Texas established to support preclinical development and future clinical operations; parent company relationships reflect a unified strategy around allogenic iMSC therapies and collaboration-driven development pathways.